Targeting Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) for the Treatment or Prevention of Alcoholic Liver Disease.

Excessive, chronic alcohol consumption can lead to alcoholic liver disease. The etiology of alcoholic liver disease is multifactorial and is influenced by alterations in gene expression and changes in fatty acid metabolism, oxidative stress, and insulin resistance. These events can lead to steatosis, fibrosis, and eventually to cirrhosis and liver cancer. Many of these functions are regulated by peroxisome proliferator-activated receptors (PPARs). Thus, it is not surprising that PPARs can modulate the mechanisms that cause alcoholic liver disease. While the roles of PPARα and PPARγ are clearer, the role of PPARβ/δ in alcoholic liver disease requires further clarification. This review summarizes the current understanding based on recent studies that indicate that PPARβ/δ can likely be targeted for the treatment and/or the prevention of alcoholic liver disease.

• Publication year

  2021

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  2021-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1248/bpb.b21-00486PMID 34719638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is type 2 diabetes an adiposity-based metabolic disease? From the origin of insulin resistance to the concept of dysfunctional adipose tissue

  2021cited by this paper
• Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review

  2021cited by this paper
• Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.

  2021cited by this paper
• Roles of peroxisome proliferator-activated receptor α in the pathogenesis of ethanol-induced liver disease.

  2020cited by this paper
• Sphingolipids and the link between alcohol and cancer.

  2020cited by this paper
• Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl‐Chain Length and Hepatic Insulin Sensitivity in Mice

  2020cited by this paper
• Signal Transducer and Activator of Transcription

  2020cited by this paper
• Alcohol effects on hepatic lipid metabolism

  2020cited by this paper
• Revealing the role of Peroxisome Proliferator-Activated Receptor β/δ in nonalcoholic fatty liver disease.

  2020cited by this paper
• The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.

  2020cited by this paper
• A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease

  2019cited by this paper
• Molecular Carcinogenesis

  2019cited by this paper
• Cyp2b-null male mice are susceptible to diet-induced obesity and perturbations in lipid homeostasis.

  2019cited by this paper
• Ethanol withdrawal mitigates fatty liver by normalizing lipid catabolism.

  2019cited by this paper
• PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation

  2019cited by this paper
• Role and mechanisms of autophagy in alcohol-induced liver injury.

  2019cited by this paper
• Regulatory mechanisms mediated by peroxisome proliferator‐activated receptor‐β/δ in skin cancer

  2019cited by this paper
• Unraveling the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) expression in colon carcinogenesis

  2019cited by this paper
• Magnolol Prevents Acute Alcoholic Liver Damage by Activating PI3K/Nrf2/PPARγ and Inhibiting NLRP3 Signaling Pathway

  2019cited by this paper
• Chronic Alcohol Consumption Inhibits Autophagy and Promotes Apoptosis in the Liver

  2018cited by this paper
• Cyp2b-Knockdown Mice Poorly Metabolize Corn Oil and Are Age-Dependent Obese.

  2018cited by this paper
• Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects

  2018cited by this paper
• Obesity and nonalcoholic fatty liver disease: current perspectives

  2018cited by this paper
• Compensatory changes in CYP expression in three different toxicology mouse models: CAR-null, Cyp3a-null, and Cyp2b9/10/13-null mice

  2017cited by this paper
• Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver

  2017cited by this paper
• The peroxisome proliferator‐activated receptor alpha agonist fenofibrate attenuates alcohol self‐administration in rats

  2017cited by this paper
• Alcoholic Liver Disease: Pathogenesis and Current Management

  2017cited by this paper
• Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis.

  2017cited by this paper
• Suppression of PPARγ-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis

  2016cited by this paper
• Pathogenesis of Alcoholic Liver Disease.

  2016cited by this paper
• Hepatic Peroxisome Proliferator-Activated Receptor Gamma Signaling Contributes to Alcohol-Induced Hepatic Steatosis and Inflammation in Mice.

  2016cited by this paper
• Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy*

  2016cited by this paper
• Docosahexaenoic acid supplementation failed to attenuate chronic alcoholic fatty liver in mice.

  2016cited by this paper
• Chronic Moderate Alcohol Intakes Accelerate SR-B1 Mediated Reverse Cholesterol Transport

  2016cited by this paper
• De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose

  2015cited by this paper
• Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium

  2015cited by this paper
• Gut-liver axis in alcoholic liver disease.

  2015cited by this paper
• Establishing the Role of PPARβ/δ in Carcinogenesis.

  2015cited by this paper
• Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.

  2015cited by this paper
• CMZ Reversed Chronic Ethanol-Induced Disturbance of PPAR-α Possibly by Suppressing Oxidative Stress and PGC-1α Acetylation, and Activating the MAPK and GSK3β Pathway

  2014cited by this paper
• Inhibition of cytochrome P4502E1 by chlormethiazole attenuated acute ethanol-induced fatty liver.

  2014cited by this paper
• PPARδ activation attenuates hepatic steatosis in Ldlr−/− mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity

  2014cited by this paper
• Insulin receptor signaling in normal and insulin-resistant states.

  2014cited by this paper
• Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.

  2014cited by this paper
• Physiological functions of peroxisome proliferator-activated receptor β.

  2014cited by this paper
• Ethanol-induced oxidant stress modulates hepatic autophagy and proteasome activity

  2014cited by this paper
• Chronic alcohol‐induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome‐proliferator activated receptor‐δ agonist treatment

  2013cited by this paper
• Regulation of cytochrome P450 2e1 expression by ethanol: role of oxidative stress-mediated pkc/jnk/sp1 pathway

  2013cited by this paper
• Bioavailability: A pharmaceutical review

  2013cited by this paper
• Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis.

  2013cited by this paper
• PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.

  2013cited by this paper
• Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis

  2012cited by this paper
• PPARs at the crossroads of lipid signaling and inflammation.

  2012cited by this paper
• Long-term management of alcoholic liver disease.

  2012cited by this paper
• Alcoholic liver disease.

  2012cited by this paper
• Cytokines in alcoholic liver disease

  2012cited by this paper
• RNA Sequencing Reveals Dynamic Changes of mRNA Abundance of Cytochromes P450 and Their Alternative Transcripts during Mouse Liver Development

  2012cited by this paper
• Oxidative Stress and Antioxidant Defense

  2012cited by this paper
• The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

  2012cited by this paper
• The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells

  2012cited by this paper
• Analysis of the peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) cistrome reveals novel co-regulatory role of ATF4

  2012cited by this paper
• Lentiviral-mediated RNAi knockdown yields a novel mouse model for studying Cyp2b function.

  2012cited by this paper
• Insulin Resistance, Ceramide Accumulation, and Endoplasmic Reticulum Stress in Human Chronic Alcohol-Related Liver Disease

  2012cited by this paper
• Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis.

  2011cited by this paper
• Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques.

  2011cited by this paper
• The emerging role of autophagy in alcoholic liver disease

  2011cited by this paper
• Alcoholic liver disease: pathogenesis and new therapeutic targets.

  2011cited by this paper
• Role of CYP2E1 in Ethanol-Induced Oxidant Stress, Fatty Liver and Hepatotoxicity

  2011cited by this paper
• The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

  2011cited by this paper
• Pathways of liver injury in alcoholic liver disease.

  2011cited by this paper
• Pathogenesis of alcohol‐induced liver disease: Classical concepts and recent advances

  2011cited by this paper
• Peroxisome proliferator‐activated receptor agonist treatment of alcohol‐induced hepatic insulin resistance

  2011cited by this paper
• Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice

  2011cited by this paper
• Constitutive Androgen Receptor-Null Mice Are Sensitive to the Toxic Effects of Parathion: Association with Reduced Cytochrome P450-Mediated Parathion Metabolism

  2010cited by this paper
• Peroxisome Proliferator-Activated Receptor Alpha Target Genes

  2010cited by this paper
• Effects of body weight and alcohol consumption on insulin sensitivity

  2010cited by this paper
• Calcific uremic arteriolopathy

  2010cited by this paper
• AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3)

  2010cited by this paper
• A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation

  2010cited by this paper
• Rat Strain Differences in Susceptibility to Alcohol-Induced Chronic Liver Injury and Hepatic Insulin Resistance

  2010cited by this paper
• Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress.

  2009cited by this paper
• Mouse carnitine-acylcarnitine translocase (CACT) is transcriptionally regulated by PPARalpha and PPARdelta in liver cells.

  2009cited by this paper
• Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

  2009cited by this paper
• PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair.

  2009cited by this paper
• Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR).

  2009cited by this paper
• Cytochrome P450 2E1 contributes to ethanol‐induced fatty liver in mice

  2008cited by this paper
• Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice.

  2008cited by this paper
• PPAR delta as a therapeutic target in metabolic disease.

  2008cited by this paper
• Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway

  2008cited by this paper
• Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice

  2008cited by this paper
• Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

  2008cited by this paper
• Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice.

  2008cited by this paper
• PPARδ as a therapeutic target in metabolic disease

  2008cited by this paper
• Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.

  2008cited by this paper
• Alcohol and lipid metabolism.

  2008cited by this paper
• Ligand activation of peroxisome proliferator-activated receptor b / d (PPAR b / d ) inhibits chemically induced skin tumorigenesis

  2008cited by this paper
• CYP2E1 and oxidative liver injury by alcohol.

  2008cited by this paper
• Insulin resistance in experimental alcohol‐induced liver disease

  2008cited by this paper
• CYP 2 E 1 and Oxidative Liver Injury by Alcohol

  2008cited by this paper
• Peroxisome proliferator‐activated receptor‐β/δ protects against chemically induced liver toxicity in mice

  2007cited by this paper

• [Elucidating the Mechanisms of Lipid Accumulation in the Liver and Evaluating Potential Drug Targets].

  2025cites this paper
• Selenium binding protein 1 (SBP1) suppresses fructose-induced metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Natural products in atherosclerosis therapy by targeting PPARs: a review focusing on lipid metabolism and inflammation

  2024cites this paper
• Elevated levels of alcohol dehydrogenase aggravate ethanol-evoked cardiac remodeling and contractile anomalies through FKBP5-yap-mediated regulation of ferroptosis and ER stress.

  2024cites this paper
• Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9

  2024cites this paper
• Targeting PPARs for therapy of atherosclerosis: A review.

  2023cites this paper
• Novel 1,2,4-oxadiazole compounds as PPAR-α ligand agonists: a new strategy for the design of antitumour compounds.

  2023cites this paper
• Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs

  2022cites this paper